Clinical Trial Update: Skin Irritation Study of GSK2894512 Cream [Phase 1]

View source ↗

Summary

Phase 1 skin irritation study of GSK2894512 cream has completed; study sponsor was GlaxoSmithKline.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• GSK2894512 cream (GSK2894512)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Dermatitis, Atopic | Phase 1 | Status: COMPLETED